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Abstract.  Previous work from our laboratories has 
demonstrated that:  (a) the striated collagen fibrils of 
the corneal stroma are heterotypic structures com- 
posed of type V  collagen molecules coassembled along 
with those of type I collagen,  (b) the high content of 
type V  collagen within the corneal collagen fibrils is 
one factor responsible for the small, uniform fibrillar 
diameter (25 nm) characteristic of this tissue, (c) the 
completely processed form of type V collagen found 
within tissues retains a large noneollagenous region, 
termed the NH2-terminal domain,  at the amino end of 
its txl  chain,  and (d) the NH2-terminal domain may 
contain at least some of the information for the ob- 
served regulation of fibril diameters.  In the present in- 
vestigation we have employed polyclonal antibodies 
against the retained NH2-terminal domain of the ot 1  (V) 
chain for immunohistochemical  studies of embryonic 
avian corneas and for immunoscreening a chicken 
cDNA library.  When combined with cDNA sequenc- 
ing and molecular rotary shadowing, these approaches 
provide information on the molecular structure of the 
retained NH2-terminal domain as well as how this do- 
main might function in the regulation of fibrillar 
structure. 
In immunofluorescence and immunoelectron micros- 
copy analyses, the antibodies against the NH2-terminal 
domain react with type V  molecules present within 
mature heterotypic fibrils of the corneal stroma.  Thus, 
epitopes within at least a portion of this domain are 
exposed on the fibril surface.  This is in marked con- 
trast to mAbs which we have previously characterized 
as being directed against epitopes located in the major 
triple helical domain of the type V  molecule.  The he- 
lical epitopes recognized by these antibodies are anti- 
genically masked on type V  molecules that have been 
assembled into fibrils. 
Sequencing of the isolated eDNA clones has 
provided the conceptual amino acid sequence of the 
entire amino end of the cd(V) procollagen chain.  The 
sequence shows the location of what appear to be 
potential propeptidase cleavage sites. One of these,  if 
preferentially used during processing of the type V 
procollagen molecule, can provide an explanation  for 
the retention of the NH2-terminal  domain in the com- 
pletely processed molecule.  The sequencing  data also 
suggest that the NH2-terminal domain  consists  of several 
regions,  providing  a structure which fits well with that of 
the completely processed type V molecule as visualized 
by rotary shadowing. 
T 
HE major component of the mature corneal  stroma 
is a striated  collagen fibril characterized  by its small, 
uniform  diameter  (25  /tm).  Because these fibrillar 
properties  are  thought  to  be required  for  corneal  trans- 
parency, elucidating  the molecular mechanism(s)  by which 
they are controlled is paramount to our understanding  of the 
development and growth of a functional  cornea, as well as 
of fibrillogenesis  in general. 
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Anatomy and Cellular Biology, Tufts University Medical School, 136 Har- 
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Striated collagen fibrils are composed largely of molecules 
of the fibrillar  collagen  class  (31) arranged  in  a  quarter- 
stagger  array (19, 22).  This  molecular arrangement  deter- 
mines certain properties of a fibril.  In itself,  however, this 
arrangement  can not be responsible for regulating  fibril di- 
ameter, because it is the structural  form of all striated fibrils, 
regardless  of their diameter. 
A number of factors have been suggested as being impor- 
tant  in  the  regulation  of fibril  diameter.  These  include 
glycosylation  of collagen molecules (26), procollagen pro- 
cessing (27, 41) and collagen-proteoglycan  interactions  (43). 
Recently, we have obtained evidence for the involvement of 
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different types of fibrillar collagen molecules, resulting in 
the assembly of what we have termed the heterotypic fibril 
(28, 29,  38, 47). 
Evidence for such an arrangement came initially from the 
observation that epitopes for mAbs directed against the triple 
helical domain of  type V collagen were antigenically  masked 
in sections of corneal stroma, as well as in a number of other 
tissues (33, 34).  Unmasking could be effected only by dis- 
rupting  fibril  structure  (3,  15,  34)  or  by  enzymatically 
removing type I collagen with a vertebrate collagenase selec- 
tive for type I collagen (13, 15). This suggested that collagen 
types I and V were coassembled in such a way that the type 
I molecules rendered epitopes on the type V molecules un- 
available for antibody binding. Double-label immunoelec- 
tron microscopy provided a definitive demonstration of such 
a heterotypic arrangement for these two collagen types (3). 
In addition, because the label for each collagen type oc- 
curred  with the  same  65-70-um  repeat  predicted by the 
quarter-stagger  model of fibril  structure,  these data sug- 
gested that an interaction existed between the two molecular 
types resulting in their coassembly. Other heterotypic com- 
binations of collagens have since been observed in cartilage 
(38),  skin and tendon (28, 29). 
We hypothesized that the coassembly of different colla- 
gens could dictate certain properties of fibrils, such as di- 
ameter (32). The structural similarities of the fibrillar colla- 
gens  would  allow them to  coassemble;  their  differences 
could stericaily influence fibrillogenesis. We also hypothe- 
sized that the high concentration of type V collagen within 
cornea (15-20% compared to <5% in other tissues [37, 46]) 
could be responsible for the small uniform diameter of the 
stromai fibrils. Our studies employing in vitro fibrillogenesis 
(2)  and corneal fibroblast cell culture (7)  support this hy- 
pothesis.  When  both  types  of  collagen  molecules  are 
copolymerized, increasing the proportion of  type V collagen 
progressively decreases the diameter of  the heterotypic fibril 
produced. 
The native, completely-processed type V collagen mole- 
cule,  as  extracted  from  tissues,  retains  a  large  pepsin- 
sensitive domain at the NH2-terminai end of its od(V) chain 
(1, 4, 8, 11, 30). We will refer to this retained portion as the 
NH2-terminai domain.l Most other fibrillar collagens, after 
processing from their procollagen forms, retain only short 
(,o20 amino acid) peptides at their ends. The in vitro hetero- 
typic fibrillogenesis experiments demonstrated that the fibril 
diameter-regulating properties of the type V collagen mole- 
cule reside largely within this NHe-terminal domain (2). 
Molecules from which this domain had been artificially re- 
moved using pepsin digestion showed little effect compared 
to native type V  molecules.  Thus,  the NH2-terminai do- 
main is a potential regulatory element. 
Others have suggested from in vivo (16, 17) and in vitro 
studies (41) that the removal ofpropeptides from procollagen 
types I  and In can influence fibrillogenesis. Because the 
1. The amino end of the pro-,l(V) chain begins at the initiation methionine 
and ends at the start of the major triple helix. It aPtwau~ to be comprised 
of three separate domains which will be referred to as the signal peptide, 
the  NH2-propeptide  (removed  during procollagen processing),  and the 
NH2-terminal  domain (retained with completely-processed  type V colla- 
gen molecules).  The three domains together will be referred to as the "entire 
amino end" of the otl(V) chain. 
rates at which the propeptides are removed can vary for 
different collagens and for different tissues, this may be one 
factor in fibril growth. It may be through a similar type of 
steric  mechanism  that  the  NH2-terminal  domain  of the 
od(V) chain limits fibril diameter. However, because this do- 
main is not removed during processing of the type V procol- 
lagen molecules,  it theoretically can maintain a  constant 
fibril diameter for an indefinite period of time.  Recently, 
Chapman (5) has presented a formal model that generalizes 
these ideas. 
In the present study, in order to examine further the prop- 
erties of type V collagen within corneal collagen fibrils, and 
to provide a basis for further studies of the molecule, poly- 
clonal antibodies have been produced which react with the 
NH2-terminal domain, the putative regulatory domain within 
the  al(V)  chain.  These  have  been  used  for  immuno- 
histochemical examination of embryonic avian corneas, and 
for immunoscreening  a chicken eDNA library. The immuno- 
histochemical analyses showed that epitopes within this do- 
main are available for antibody binding, even when the mole- 
cule is present within the heterotypic fibrils of the corneal 
stroma. This confirms that the NH2-terminal  domain does 
remain associated with the molecule after its assembly into 
fibrils, and that at least a portion of it is exposed at the fibril 
surface. 
Sequencing of the eDNA clones has provided the concep- 
tuai amino acid sequence of the entire amino end of the 
chicken od(V) chain. The chicken sequence has a number of 
similarities to the recently published human sequence (18, 
45),  but also a number of differences. Analysis of the se- 
quence data suggests the presence of several separate regions 
within the amino-terminai end and the location of a putative 
propeptidase cleavage site which, if used in removal of the 
propeptide portion of  the amino end, provides an explanation 
as to why the NHe-terminai domain remains as a part of the 
completely processed type V collagen molecule. 
Materials and Methods 
Antibody Production and Characterization 
Tendons from 18-d chick embryos were extracted at 0°C in 4 M guanidine 
hydrochloride,  0.05 M "Iris HC1, pH 7.5, 0.02 M EDTA, 0.01 M N-ethyl- 
maleimide, 0.001 M phenylmethyl sulfonyl fluoride, and 0.005 M benzami- 
dine, and the supernatant was dialyzed against 4 M urea, 0.05 M Tris-HC1, 
0.02 M EDTA, 0.13 M NaCl, pH 7.5. (buffer A). Triton X-100 (final concen- 
tration 0.1%  ) was added to the supernatant along with an aliquot of radiola- 
beled tendon extract to facilitate monitoring of the separation.  The sample 
was loaded onto a DEAE-cellulnse column (2  x  20 cm) and was washed 
with buffer A plus Triton X-100. Raising the NaC1 to 0.21 M eluted, in the 
terminology of Fessler and Fessler (8), p-collagen V (a partially processed 
form), f-collagen V (the final form which still retains the NH2-terminal do- 
main), and a trace of sulfated procollagen V, as determined by SDS PAGE. 
Bands corresponding to the partially and completely processed forms of 
the od(V) chains were cut out of the gel and washed with H20 and several 
changes of PBS at 4°C.  The gel pieces were  fragmented in PBS and 
emulsified  in complete Freund's adjuvant  (first injection) or incomplete 
Freund's adjuvant (subsequent injections).  Rabbits were injected intrader- 
really and intramuscularly in the thigh muscles at 16-d intervals. Blood was 
collected 14 d after the third and subsequent injections,  and the serum was 
isolated. 
These antibodies will be termed the anti-NH2-cd(V) antibodies. Charac- 
terization by Western blotting showed them to be specific  for the NH2- 
terminal domains of the partially and completely  processed forms of the 
al(V) chains. They recognized the intact ped(V) and fal(V) chains in re- 
duced or nonreduced form. They also reacted with the prowl(V) chain, as 
would be expected.  They recognized  the NHe-terminal  domains released 
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tion and immunoprecipitated the partially and completely processed forms 
of type V. They did not show reactivity with any of the forms of the closely 
related al'(V) chain (The cd'(V) chain is thought to be very similar to the 
cd(V) chain (12). It is found in some tissues,  but if it is present in cornea, 
it is in very small amounts [unpublished observations].) nor with the non- 
eollagenous peptides derived from this chain. They also failed to react with 
the major triple helical domain of chains from which the noneollagenous 
peptides had been removed by limited pepsin digestion. 
Immunohistochemical  Procedures 
Rotary shadow electron microscopy  of antibody binding to the completely 
processed, tissue form of type V collagen was performed as previously de- 
scribed (2, 36).  Immunofluorescence  and immunoelectron microscopy  of 
corneas were also performed as previously described (3). For immunoelec- 
tron microscopy,  both ultraeryomicrotomy and pre-embedding were em- 
ployed.  The anti-NH2-al(V) antibodies were used at dilutions of 1:150 or 
1:300; the mAbs were used at 10-25 #g/ml. 
Molecular Biology 
The anti-NH2-cd(V)  antibodies were utilized for immunoscreening a 10-d 
chicken embryo eDNA library (Clonetech Laboratories, Inc., Paio Alto, 
CA) constructed in Xgtll. The library was plated using Escherichia coli 
strain YI090 onto five 150-ram dishes at a density of 50,000 plaque-forming 
u/plate.  The plates were incubated at 42°C for 3.5 h, and then the produc- 
tion of fusion proteins was  induced by the addition of IPTG-contaihing 
nitrocellulose filters (Millipore Corp., Bedford, MA) and lowering the incu- 
bation temperature to 370C. The plates were incubated for an additional 
3.5 h and then were removed,  washed in TBS (20 mM Tris HCI pH 7.5, 
150 mM NaC1) and stored overnight at 4"C in 2% blocking reagent made 
up in TBS (Boehringer Mannheim  Corp., Indianapolis, IN). A duplicate set 
of nitrocellulose filter lifts was taken and processed.  The filters were reacted 
overnight at 4"C with the anti-NH2-al(V) antibodies diluted 1:400 in 2% 
blocking reagent.  The  plaques  which  had  bound  the  antibodies were 
identified employing an alkaline phosphatase antibody detection kit (pico- 
Blue Immunoscreening Kit)  used according to the suppliers (Stratagene 
Inc., La Jolla, CA) direction. Positive plaques were cloned and identified 
using the same protocol. In preparation for sequencing,  inserts in the kgtll 
vector were amplified by PCR using vector-specific primers and cloned into 
the plasmid vector pCR1000 using the TA cloning system (Invitrogen,  San 
Diego,  CA). 
By sequencing and size determination on agarose gels, none of the im- 
munoisolated clones appeared to encode the entire amino end of the al(V) 
chain (see Results).  Therefore,  one of these clones (V-2.3.2) was used to 
screen a 13-d embryonic chicken corneal eDNA library we bad previously 
constructed in the vector XZAPrl.  For this, the eDNA insert (1.6 kb) of 
clone V-2.3.2 was amplified by PCR using a GeneAmp gene-amplification 
kit (Perkin-Elmer/Cetus Corp., Norwalk, CT) and then eleetro-eluted  from 
a 1% Agarose gel. The purified insert was labeled with 32p by nick transla- 
tion and used to probe plaque lifts of the hZAP eDNA library.  Hybridiza- 
tions were done overnight at 65°C in 5×  SSC containing 1% N-lauroyl- 
sarcosine.  Four washings were done at the same temperature: two in 3× 
SSC, 0.5%  N-lauroylsarcosine  followed by two in 3×  SSC alone.  Bound 
radioactivity was  visualized  by autoradiography.  Positive  plaques  were 
cloned  and  the  insert-containing Bluescript plasmids  were  rescued  by 
helper-phage mediated in vivo excision. 
Sequencing was performed using either the Sanger dideoxy method (42) 
as modified for the Sequenase kit (US Biochemical Corp., Cleveland,  OH) 
or  with Taq polymerase using a  dsDNA  Cycle  Sequencing  System  kit 
(GIBCO BRL, Gaithersburg, MD). For the cycle sequencing method, the 
parameters used for the amplification cycles were those recommended by 
the supplier, except that the timing for the denaturation and elongation steps 
was  increased from 30--50 s.  The insert-containing plasmids to be se- 
quenced by the dideoxy  method were prepared by the lysozyme  "Boiling 
Method"; those to be sequenced by the PCR method were prepared by the 
"Alkaline Lysis Method" (35). 
Oligonueleotide  primers were synthesized on an automated synthesizer 
(PCRMATE, model 391, Applied Biosystems, Inc., Poster City, CA). They 
were purified with oligonucleotide  purification  cartridges (Applied Bio- 
systems,  Inc.). 
The sequenced  samples were electrophoresed on 5 % denaturing acryl- 
amide wedge gels and visualized by autoradiography.  The autoradiograms 
were read and the data recorded with the aid of the DNA Prosean Scanner 
and Sequencing Package (DNA Proscan, Inc., Nashville, TN). Some of the 
analyses of the data were performed using the GCG software package and 
Chou-Fasman prediction (6). 
Results 
Immunohistochemistry 
Antibodies. The polyclonal antibodies employed (referred to 
as the anti-NH2-otl(V) antibodies) are directed against epi- 
topes present in the NH2-terminal domain retained by the 
completely-processed (tissue) form of the od(V) chain (see 
Materials and Methods). The two anti-type V mAbs used 
(V-DH2 and V-AB12) have been previously characterized as 
being  directed  against  triple-helical,  collagenous  deter- 
minants within the type V molecule (34,  36). 
Rotary Shadowing. For certain of the proposed studies, it 
was desirable to know whether the determinants to which 
these antihelical mAbs bind are located near the NH2- or 
the COOH-terminal ends of the molecule. Thus, we per- 
formed rotary shadowing of their binding to native type V 
molecules with the attached NH2-terminal  domain. In ro- 
tary shadowed preparations,  the NH2-terminal domain re- 
tained with the native type V molecule appears to be a mul- 
tidomain structure consisting of a kink, followed by a short 
rod, terminating in a ball (Fig.  1, A and B). It is ,,ol7-nm 
long,  a  size which fits  well with previous determinations 
made  from  rotary  shadowed  preparations  (2)  and  from 
segment-long-spacing crystallites (4). The anti-type V mAbs 
(Fig. 1, C and D) bind near the opposite end of the molecule 
placing their binding sites ,,o15% from its COOH-terminal 
end. 
Immunofluorescence. Immunofluorescence analyses were 
used to compare the corneal tissue reactivities of the NH2- 
terminal anti-NH2-od(V)  antibody with that of the antibod- 
ies to the helical sites.  Two different ages of embryonic cor- 
neas were examined, 11-d embryonic corneas in which the 
corneal stroma is hydrated, swollen and rapidly undergoing 
matrix deposition, and 17-d embryonic corneas in which the 
stroma is mature and has attained its compact state. 
At both times of development, the anti-NH2-od(V)  anti- 
bodies and the anti-helical antibodies produced strikingly 
different patterns of immunoreactivity in untreated tissues. 
Whereas the anti-helical antibodies require a pretreatment 
resulting in fibril disruption, as previously described (34), 
the anti-NH2-~xl(V) antibodies reacted with the normal, un- 
treated corneal stroma. This can be seen by comparing the 
fluorescence micrographs in Fig. 2, A and B (reacted with 
the different antibodies in the absence of tissue unmasking) 
with the micrographs in Fig. 2, C and D  (reacted with the 
antibodies after unmasking by fibril disruption). Fig. 2, E 
and F, show control sections which were treated respectively 
with a mAb against type IV collagen and preimmune rabbit 
serum. The mature, 17-d corneal stroma behaves identically 
(data not shown). 
Imraunoelectron Microscopy. By  immunoelectron mi- 
croscopy of corneal stromas, we previously demonstrated 
that the antibodies against the helical epitopes on type V col- 
lagen reacted with the 24-nm striated fibrils, but again, only 
after fibril structure was partially disrupted (data not shown, 
but see 3,  13).  The anti-NH2-txl(V)  antibodies also react 
with the 24-nm striated fibrils (Figs. 3, B and D) but, consis- 
tent with the immunofluorescence results, they need not be 
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monoclonal antibodies bound to native type V collagen molecules 
extracted from corneas of  lathyritic chicken embryos. A and B show 
the type V molecules themselves. C and D show molecules that had 
been reacted with mAb directed against the triple-helical  domain 
of the molecule. Arrows point to the kink demarcating the start of 
the NH2 terminal domain.  Note that the antibody binds near the 
opposite end of the molecule. Bar, 50 nm. 
disrupted.  This was observed whether pre-embedding im- 
munolocalization of conventional plastic sections (Fig. 3 B) 
or postembedding localization of ultrathin cryosections was 
employed (Fig.  3,  C and D). 
These data are consistent with the NH2-terminal domain 
of the od(V) chain being retained after the molecule has be- 
come incorporated into fibrils and, in addition, demonstrate 
that at least a portion of this domain is exposed on the fibrirs 
surface. 
Immunoisolation and Sequencing of  cDNA Clones for 
the Complete NH2 terminal Propeptide 
To  determine  the  structure  of the  NH2-terminal  domain, 
and that of the entire amino end of the od(V) chain, we used 
the  anti-NH2-al(V)  antibody  to  irnmunoisolate  cDNA 
clones,  which were then sequenced.  Initially, we screened 
two eDNA libraries,  one  constructed  in  kgt11  from  10-d 
chicken  embryo mRNA,  and  one  constructed  in  XZAPII 
from  13-d  chicken  embryo corneal  rnRNA.  Ten  positive 
plaques were identified and cloned from the kgt11  library; 
the XZAP library gave none.  Several positive clones were 
partially sequenced. Each contained a collagenous sequence 
at its Y-end and a noncoUagenous sequence at its 5' end (Fig. 
4).  None, however, appeared to be large enough to encode 
a sequence of the size required for the entire amino end, as 
estimated from the biosynthetic studies on the molecule (8), 
and none contained a sequence encoding an in-frame initia- 
tion methionine codon. 
Figure 2.  Immunofluorescence  micrographs  of corneal  sections 
from 11-d  chicken embryos reacted with anti-type V mAbs (V-AB12 
and V-DH2) directed against the helical domain (,4 and C), or with 
anti-NH2-od(V)  antibodies  (B  and  D).  C  and  D  had  been 
pretreated with 0.1 N HA_c  to disrupt fibrillar structure (34); A and 
B had no pretreatment.  As controls, the section in E was reacted 
with an anti-type IV collagen antibody (14); the section in F was 
reacted with preimmune  rabbit serum. 
One of these clones,  V-2.3.2.,  was used to rescreen the 
corneal kZAP library by hybridization. By this method, five 
positive plaques were now identified.  Upon sequencing the 
largest of these clones, V105.1.1 (Fig. 4), a methionine codon 
was found, one base in from the 5' end. This clone was then 
sequenced past the point where it entered the major collage- 
nous domain. Overlaps occurring between the kgtl 1 and the 
~ZAP clone inserts were identical in sequence. 
The sequence of clone V105.1.1  provided the conceptual 
amino acid sequence of the entire amino end of the chicken 
cd(V) chain. (The nucleotide sequence can be obtained from 
GenBank under the accession number Z21816.) In Fig. 5, the 
amino acid sequence is compared with that of the human (18) 
which has not become available. 
Structure  and Domains.  As can be seen from the trans- 
lated  amino  acid  sequence,  the  entire  amino  end  of the 
chicken od(V) chain consists of 554 amino acid residues to 
the first triple-helical glycine of the main collagenous do- 
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micrographs  of corneal  sec- 
tions  reacted  with  either 
preimmune serum (A) or an- 
tisera  directed  against  the 
NH2-terminal  domain  of the 
cd(V)  chain  (B-D).  All  sec- 
tions were reacted with a col- 
loidal gold-labeled secondary 
antibody. A and B are conven- 
tional plastic sections of pre- 
embedded  preparations.  C 
and  D  are  ultrathin  cryo- 
sections  employing  postern- 
bedding  localization.  Bar, 
100 nm. 
V2.3.2 
It  Im  It 
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Figure 4. A schematic diagram showing the structure of the entire 
amino end of the pro-t~l(V) chain, deduced from cDNA sequenc- 
ing. Shown also is the strategy employed to obtain the sequence. 
V2.3.2 and V105.1.1 are two of the cDNA clones. V2.3.2 was ob- 
tained by immunoisolation; V105.1.1 was obtained by hybridization 
screening with V2.3.2.  Clone V105.1.1 provided an uninterrupted 
sequence of  the entire amino end of  the pro-al(V) chain. The major 
regions  of the domain  are designated:  (SP) signal peptide,  (Cys 
Rich) cysteine rich, (Tyr Rich) tyrosine rich, (Short THs) short tri- 
ple helices,  and (AH)  or-helix. The arrows show the  sequencing 
steps used to obtain the entire  sequence of clone V105.1.1. 
main. This is four residues more than in the human.  From 
the translated sequence,  we have deduced that this peptide 
is comprised of several regions, schematically diagrammed 
in Fig. 4. 
Starting at the NH2 terminus, the first of these is the sig- 
nal peptide which consists of 33 amino acids, three less than 
the human. It contains a number of substitutions compared 
to the human, but at critical positions, the substituted amino 
acids maintain the characteristics required for a signal pep- 
tide (48). 
The next major region is cysteine-containing, extends ap- 
proximately to residue 249,  and is highly conserved when 
compared to the human (88 % identity). It contains all four 
cysteines of the NH2-terminai propeptide as well as the sin- 
gle consensus sequence for glycosylation. All of these are 
conserved  across  the  two  species.  By  Chou-Fasman pre- 
diction (6), this cysteine-containing region has numerous in- 
termixed hydrophobic and hydrophilic stretches, and numer- 
ous regions of beta sheet. 
The high degree of interspecies amino acid conservation 
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301 KETTEVPEE  ......  LTPTPTEAAPMPETSEGAGKEEDVGIGDYDYVP.S  343 
347 EEYFTPLPYEDINYNEEVD~GGLTENAVEAELPTSTVITYNETD  ....  A 392 
I I II II I  I  I  II IIII  I I 
344 EDYYTPSPYDDLTYGEGEENPDQPTDPGAGAEIPTSTADTSNSSNPRPpp  393 
--  ~)  .. 
393 AQGGDDLDKDFTEETIKEYDGNYY..~'DRTVSP.DIGPGMPANQDTIYE  439 
IIII  IIIII  IIII  IIIIII  IIIIIIIIIIIIII 
394 GEGADDLEGEFTEETIRNLDENYYDPYYDPTSSPSEIGPGMPANQDTIYE  443 
440 GIGGPRGEKGQKGEPAIIEPGMLVEGPPGPEGPAGLPGPPGPTGPVGLMG  489 
IIIIIIIIIIIIIIII IIIIII:IIIIIIIIIIIIIIIII  II I  I 
444 GIGGPRGEKGQKGEPAIIEPGMLIEGPPGPEGPAGLPGPPGTMGPTGQVG  493 
490 DPGERGPPGRPGLPGADGLPGPPGTMLMLPFRFSGGGDAGSKGPMVSAQE  539 
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII IIIIIIIIIIIIIIII 
494 DPGERGPPGRPGLPGADGLPGPPGTMLMLPFRFGGGGDAGSKGPMVSAQE  543 
540 AQAQA  I  LQQARLALR~G  PAG  PMGLTGRPG P  I  GPQGSGG  576 
IIIIIIIIIIIIIIIIIIIIIIIIIIII II IIII 
544 SQAQAI  LQQARLALRG  PAGPMGLTGRPGPVGPPG  SGG  580 
Figure 5. Comparison of the translated amino acid sequences for 
entire amino end of the pro-cd(V) chain of the chicken (top se- 
quence) and the human (18) (lower  sequence). Arrowheads demar- 
cate the end of the signal peptide and the start of the major triple 
helix.  Cysteines  are  designated  with  asterisks;  alanine-glu- 
tamine/proline-glutamine sequences have overhead lines, and the 
glycosylation site is boxed. Tryosines have dots above them; those 
which are likely to be sulfated have circles surrounding the dots. 
rapidly decreases in the next region (46%  identity). This 
tyrosine-rich region begins at a putative propeptidase cleav- 
age site, the proline-glutamine at positions 249-250 (see be- 
low and Discussion). It extends for ,x,175 residues to a site 
•15  amino acid residues before a region consisting of three 
short triple helices. When compared to the human sequence, 
this region is found to contain numerous amino acid substitu- 
tions, one insertion of six amino acids not found in the hu- 
man and three deletions of one, two, and four amino acids 
respectively. Of the tyrosines in this region, at least four, and 
possibly six, are likely sites for sulfation, based on the con- 
sensus features of sulfation sites (24, 25). All except one are 
conserved between  the  two  species.  This  region  is  also 
highly hydrophilic as determined by Chou-Fasman predic- 
tion  and  is  likely  to  be  retained  with  the  completely 
processed type V  collagen molecule (see Discussion). 
Table L Propeptide Cleavage Sites (PQ and AQ) and Amino 
Acids at Positions -2 and -3 
ctl(I)  Bovine  F  A  P  Q 
a2(I)  Chick  F  A  A  Q 
cd(II)  Xenopus  F A A  Q 
c~2(V) (proposed)  Human  F  S A  Q 
t~l(m)  Bovine  Y  A  P  Q 
otl(V) (proposed)  Chick (249-250)  D  A  P  Q 
The carboxyl-most regions, which again are highly con- 
served between the species (94 % identity), consist of short 
collagenous stretches (three) interrupted by noncollagenous 
ones (see Fig. 4 "Short THs'). The last of  the noncollagenous 
regions is short and has a strong tendency towards or-helix 
formation (Fig. 4, AH). It immediately precedes the major 
collagenous domain of  the molecule, and contains a potential 
propeptidase cleavage site, the alanine-glutamine at position 
537-538, but one which we do not think is utilized (addressed 
next, and see Discussion). 
Potential Propeptidase Cleavage Sites 
To obtain information on which portion of the amino end of 
the  od(V)  chain  is  removed as  the  NH2-propeptide  and 
which portion is  retained with  the  completely processed 
molecule as the NH2-terminal domain, we examined the se- 
quence  for  alanine-glutamine  and  proline-glutamine  se- 
quences.  These are the sites in the chains of procollagen 
types I-lII that are thought to be cleaved by NH2-terminal 
procoUagen peptidases (23, 40, 44, 50). We also examined 
the amino acids at positions  -2 and  -3  from these sites, 
since Morikawa et al.  (39) have provided evidence that a 
phenylalanine at position  -3 appears to be crucial for the 
action of the NH2-terminal type I procollagen propeptidase. 
Seven  alanine-glutamine  or  proline-glutamine  sequences 
were found (demarcated in Fig.  5 by overhead lines), but 
only three of these had counterparts in the human sequence 
(one at position 249-250, a second at position 53%538 and 
a  third at 542-543).  No  site,  however, has an associated 
phenylalanine at position  -3  (Table I).  Comparing these 
data with the protein processing data of others suggests to 
us that the site at position 249-250 is likely to be the one 




The morphological data from both immunofluorescence and 
immunoelectron microscopy demonstrate that in the hetem- 
typic type I  +  V  corneal collagen fibrils, a portion of the 
amino end of the pro-cd(V) chain is retained with the type 
V  molecule as  the  NH2-terminal domain.  The data  also 
demonstrate that at least some epitopes in this domain are 
exposed on the surface of such fibrils. The extent to which 
this domain and its adjacent collagenous domain are exposed 
is not yet known. We do know, however, that a portion of the 
helical domain of the type V collagen molecules is buried 
within these fibrils. In the least, this includes the region to 
which our anti-helical mAbs bind. As shown in the present 
study, this is near the COOH-terminal end of the molecule. 
The Journal of Cell Biology, Volume 121, 1993  1186 Figure 6. Three views of a proposed model for the arrangement of type V collagen molecules within a heterotypic type I +  V collagen 
fibril. A and B show the fibril in longitudinal view; C shows the fibril in cross-section. The type I molecules are colored beige; the type 
V molecules are colored red. The type V molecules have the retained NH2-terminal domain extending perpendicular to the long axis. 
The type V molecules are arranged such that their triple-helical domain lies within the interior of the fibril and their NH2-terminal do- 
main extends through a hole zone to the fibril surface. In B, the type I molecules have been rendered transparent, thus, allowing full visual- 
ization of the interior type V molecules. 
The buried region also includes site(s) which are cleaved by 
a type V collagen-degrading collagenase (13). Both the anti- 
helical mAb-binding sites and the type V collagen-degrading 
collagenase cleavage site(s) can be exposed by the removal 
of some of  the type I collagen with a collagenase which selec- 
tively cleaves type I molecules (13). This suggests that within 
type I  +  V heterotypic collagen fibrils at least a portion of 
the triple-helical domain of each type V collagen molecule, 
and possibly the entire triple-helical domain of each, lies in- 
terior to a  surface of type I collagen molecules. 
At least two models can be proposed for the structure of 
a heterotypic type I +  V collagen fibril which are consistent 
with these data. In one model, both types of collagen mole- 
cules would be arranged overlapping and at an angle to the 
fibrillar axis, as has been previously suggested for collagen 
fibrils  in  general  (5).  If the  NH2-terminal domain of the 
type V  molecules were directed outward, it would explain 
the presence of this region at the fibril surface. This model, 
however, also predicts that one end of the type I  collagen 
molecules would be buried within such a fibril, and this is 
not consistent with our observations. Two anti-type I colla- 
gen antibodies, directed against epitopes near opposite ends 
of the molecule, both label fibrils at intervals along the sur- 
face indicating that both ends of this molecule are exposed 
on the fibril surface (unpublished observations). 
An alternative model which we consider more likely is di- 
agrammed in Fig. 6. In this model, the type I and type V mol- 
ecules are arranged parallel to one another.  This requires 
that the entire triple-helical domain of the type V molecule 
be buried within the fibril,  and that type I  molecules are 
completely exposed along the fibril's surface. In such an ar- 
rangement,  for the  retained  portion  of the  NH2-terminal 
domain of the type V collagen molecules to be exposed at 
the fibril's surface, they must extend outward through the 
hole zones of the fibril. Hole zones are an inherent structural 
element of striated collagen fibrils and are formed by the in- 
complete overlapping of collagen molecules when arranged 
in a quarter-stagger, fibrillar array (19).  The rotary shadow- 
ing evidence and sequencing data (discussed below) suggest 
that the NH2-terminal domain of the or(V) chain consists of 
a flexible hingelike region followed by a short collagenous 
sequence ending in a tyrosine-rich region. The hinge could 
allow the peptide to project away from the major axis of the 
molecule and the short triple-helical domain could serve as 
an extension through the hole zone, placing the tyrosine-rich 
domain at the fibril's surface. 
Regardless of which model, if either, is correct for the het- 
erotypic type I  +  V fibrils, the data are consistent with the 
proposition that  a  region of the  NH2-terminal domain on 
the  fibril  surface  regulates  fibril  diameter  by  sterically 
preventing the further addition of collagen molecules. It is 
also  possible  that  the  presence of highly  charged  sulfate 
groups on the tyrosines in this region (9, 10) also inhibits fur- 
ther accretion of collagen molecules to the surface. 
Sequencing of cDNAs 
The conceptual translation product derived from the eDNA 
clones encoding the amino end of od(V) chain has provided 
information about the size of the retained NH2-terminal do- 
main.  It also explains why this occurs. 
The sequencing data, when coupled with analyses of the 
protein structure and processing of type V collagen (4, 8, 11, 
30) suggest that the portion of amino end which is retained 
with molecules incorporated into a fibril is likely to derive 
from  cleavage  of  the  proline-glutamine  site  at  position 
249-250.  The retained NH2-terminal domain would there- 
fore include  the  tyrosine-rich and  short  triple-helical re- 
gions. 
Fessler et al.  (9,  10) have reported that tyrosines in the 
amino end of the od(V) chain are sulfated, and that most of 
these are retained after the molecule has undergone com- 
plete processing. The sequencing data show that all of the 
tyrosines capable of undergoing sulfation (24, 25) are con- 
tained within the tyrosine-rich region (see also reference 45) 
adjacent  to  this  putative  propeptide  cleavage  site.  Even 
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conserved between the chick and the human (46% identity), 
all but one of the potential tyrosine sulfation sites axe con- 
served. Also, its highly hydrophilic nature would be consis- 
tent with a location at the surface of a fibril. 
Analyses of the size of the NHz-terminal domain retained 
with the completely processed ~xl(V) chain have produced dis- 
parate results. The basis for these differences is unknown, 
but one possibility is that developmental and tissue-specific 
differences exist in posttranslational modifications, such as 
in the sulfation of the tyrosines. Broeck et al. (4) examined 
the type V collagen extracted from bone and other tissues of 
mature chickens that had been made lathyritic over a period 
of weeks. All of the type V molecules contained od chains 
with a bacterial collagenase resistant peptide of 18 KD as de- 
termined by SDS PAGE. 
Germane to the present study, we have extracted a similar 
size  chain  from  lathyritic chicken  corneas  (unpublished 
data). The 18-KD peptide fits well with the size of the col- 
lagenase resistant region ('~190 amino acid residues) one 
would expect if the putative peptidase cleavage site utilized 
during  procollagen  processing  were  the  one  at  position 
249-250.  If so, then the short collagenous regions are also 
retained with the processed molecule. By rotary shadowing 
analyses, the type V molecules extracted from lathyritic cor- 
neas show a substructure within the NH2-terminal domain 
consisting of a hinge, followed by a short rodlike stretch and 
finally a ball. The conceptual amino acid sequence suggests 
that the hinge is located within a  short (20  amino acid) 
stretch adjacent to the major triple helical domain of  the mol- 
ecule. By Chou-Fasman prediction, this stretch has a strong 
tendency  towards  or-helix  formation.  The  short,  rodlike 
stretch  is  likely  formed  by  the  three  small  collagenous 
regions with the ball being the tyrosine-rich domain. 
If the proline-glntamine at position 249-250 is the cleav- 
age site which is utilized, it most likely requires a different 
NH2-procollagen peptidase than the one utilized for type I 
procollagen. The specific sequence required for cleavage by 
the propeptidase which cleaves the od(I) and the ot2(I) chains 
of type I collagen is the only one that has been examined ex- 
perimentally (39). The results suggest that in addition to the 
amino  acids  immediately flanking the  cleavage  site,  the 
phenylalanine located at position -3 is also required. Pre- 
sumably, in type III collagen, the substitution of a tyrosine 
at -3 in the od(III) chain is the reason that this molecule is 
cleaved not by the type I collagen propeptidase but by an- 
other enzyme (20, 40). Theoretically, other amino acids sur- 
rounding the peptide bond which is cleaved might also be im- 
portant  in  determining  specificity,  as  has  recently  been 
shown for the vertebrate collagenase cleavage site in type I 
collagen (51).  It seems likely that yet another procollagen 
peptidase is involved in the processing of the NH2-terminal 
end of the al(V) chain. 
Comparison of the sequences for the pro-txl(V)  and pro- 
c~2(V) chains of the type V procollagen molecule show that 
the amino end of the or2 chain is less than half the size of 
that of the od chain. Moreover, in the amino end of the pro- 
a2(V) chain there is no site homologous to that proposed to 
undergo cleavage in the pro-txl(V).  In the pro-tx2(V)  chain, 
however,  a  complete  consensus  sequence  does  exist  for 
cleavage by the type I collagen propeptidase (49), but this 
site is located near the major triple helix (i.e., in a telopep- 
tidelike region). Studies on processing of the type V procol- 
lagen molecule suggest that cleavage of  the o~2(V) propeptide 
is more rapid than is that of the .l(V) chain. Within a pro- 
type V  molecule of chain  composition  [pro-.l(V)]2pro- 
o~2(V), cleavage of the pro-o~2 chain at the NH2 telopeptide- 
like site, but not the two pro-od chains, might be a factor in 
producing the flexibility for forming the kink observed to ex- 
ist between the NH2-terminal domain and the major triple- 
helical  domains  of type  V  molecules  viewed  by  rotary 
shadowing. 
Whether the putative cleavage site in the amino end of  pro- 
od(V) chain requires a unique procollagen peptidase remains 
to be determined, but there is a precedent for unique en- 
zymes acting on type V collagen. Another enzyme-mediated 
alteration of type V collagen, its degradation, employs a col- 
lagenase different from the one that cleaves most of the other 
fibrillar collagens 03,  21).  The isolation oi' a procollagen 
peptidase specific for the putative cleavage site in the od(V) 
chain would provide a critical test for some of the sugges- 
tions raised here. 
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